Oritavancin compared against vancomycin for skin infections

09/10/2013 | SkinAndAllergyNews.com

The effectiveness of single-dose intravenous oritavancin was similar to that of seven- to 10-day treatment with intravenous vancomycin for acute bacterial skin and skin structure infections, a multicenter study found. The most common adverse events reported in the oritavancin group included nausea, diarrhea and headache. Oritavancin was "well-tolerated, with a safety profile similar to vancomycin," lead author Dr. G. Ralph Corey reported at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

View Full Article in:

SkinAndAllergyNews.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA